In an interview with finance website Deal Street Asia, Singapore-headquartered drug development firm Asian Pharmaceuticals’ CEO Dr Carl Firth discussed why he took the company public in Taiwan and not Singapore, Europe or the US. Key reasons according to Firth included Taiwan being one of the world leaders in terms of biotech listings and being welcoming to foreign issuers. Also, Taiwan’s equivalent of NASDAQ, the TPEx (Taipei Exchange), had better liquidity for major biotech firms than most other Asian and European bourses, even surpassing the NASDAQ at times.
Read more at dealstreetasia.com. xx